Avantor Unveils Major Expansion in Hydration Solutions During DCAT Week 2025

Avantor, Inc., a global leader in life sciences and advanced technology products and services, has officially revealed its recently completed hydration expansion at its key manufacturing site in Gliwice, Poland. This announcement was made at the esteemed Drug, Chemical Associated Technologies Association (DCAT) Week 2025, running from March 17-20 in New York City. Dr. Ger Brophy, head of Avantor's Scientific Advisory Board, delivered the key highlights during the Member Company Announcement Forum on March 17.

The new high-tech production facility at the Gliwice site is a groundbreaking addition that significantly boosts its capability to produce United States Pharmacopoeia (USP) purified water and Water for Injection (WFI)-based hydration solutions. Designed to meet the increasing demand for such high-purity solutions, the expanded facility quadruples the site’s production capacity. These hydration solutions play a critical role in various biopharma processes, such as buffer preparations, cell culture media, and clean-in-process (CIP), ultimately contributing to the stability, efficacy, and safety of vital biologics and therapies.

Benoit Gourdier, the Executive Vice President of Avantor’s Bioscience Production Segment, emphasized the importance of this investment. He commented, “This latest investment strengthens our global manufacturing network, building important capacity and bringing our operations closer to customers.” The expansion aims not only to ensure reliable high-quality product supply but also to solidify Avantor's position as a trusted collaborator with biopharma manufacturers that produce transformative therapies.

In recent years, Avantor has committed substantial resources to enhance its global production capabilities, catering to the evolving demands in bioprocessing for drug manufacturers. The Gliwice expansion complements a similar project in Aurora, Ohio, which added considerable capacity for hydrated solutions to serve the North American market. Furthermore, Avantor’s Phillipsburg, N.J. facility has seen production capacity of synthesized salts double, thereby reinforcing the hydration manufacturing process.

This expansion in Poland is not just about increasing output; it also reflects Avantor's strategic approach to bolstering innovation and research capabilities. In November 2024, the company inaugurated a new 60,000 square-foot Bridgewater Innovation Center in New Jersey, which effectively doubled its previous lab and pilot plant capacity. This state-of-the-art center is designed for enhanced collaboration and bioprocessing innovation across the biopharmaceutical spectrum, facilitating upstream and downstream development, analytical testing, and viral vector research. Consequently, the center accelerates the scale-up and customization across all stages of bioprocessing workflows.

Overall, Avantor is not merely a supplier of life science tools; it is a pivotal partner in the scientific journey towards groundbreaking advancements in healthcare and technology. As it continues to grow its portfolio of mission-critical products and services, Avantor works collaboratively with over 300,000 customers in 180 countries, facilitating some of the most significant research and production activities worldwide.

For more details on Avantor’s offerings and initiatives, visit their official website at avantorsciences.com. Follow them on social media platforms like LinkedIn, Twitter, and Facebook to stay updated on their latest news and innovations.